Table of Content:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Friedreich’s Ataxia Market: Gene Therapy Segment Market Trends, Size, and Future Outlook
- Gene Therapy Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Gene Therapy Segment Definitions, Technology Landscape
- Gene Therapy Segment Market Drivers
- Clinical trial initiations
- Regulatory approvals
- Increasing R&D by companies like Pfizer, Voyager Therapeutics
- Gene Therapy Segment Market Restraints
- High costs
- Manufacturing challenges
- Lengthy development timelines
Chapter 4. Friedreich’s Ataxia Market: Symptomatic Treatment Segment Market Trends, Size, and Future Outlook
- Symptomatic Treatment Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Symptomatic Treatment Segment Definitions
- Symptomatic Treatment Segment Market Drivers
- Launch of new antioxidant and neuroprotective drugs
- Focus on improving symptom relief
- Approvals for new formulations and delivery mechanisms
- Symptomatic Treatment Segment Market Restraints
- Lack of disease-modifying capabilities
- Failure of some candidates in late-stage trials
- High placebo effect in symptom-based trials
Chapter 5. Friedreich’s Ataxia Market: Pipeline Drugs Segment Market Trends, Size, and Future Outlook
- Pipeline Drugs Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Pipeline Drugs Segment Definitions
- Pipeline Drugs Segment Market Drivers
- Robust company pipelines
- Novel mechanisms like gene editing
- Orphan drug incentives supporting development
- Pipeline Drugs Segment Market Restraints
- Slow progress to late-stage trials
- High clinical trial failure rates
- Reimbursement challenges at launch
Chapter 6. Friedreich’s Ataxia Market: Hospital Pharmacies Segment Market Trends, Size, and Future Outlook
- Hospital Pharmacies Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Hospital Pharmacies Segment Definitions
- Hospital Pharmacies Segment Market Drivers
- Increasing hospital dispensing for orphan drugs
- Rising in-hospital administration of injectable drugs
- Hospital pharmacies as a reliable distribution channel
- Hospital Pharmacies Segment Market Restraints
- Low volumes due to small patient share
- Hospital budget constraints
- Preference for retail pharmacies for outpatient dispensing
Chapter 7. Friedreich’s Ataxia Market: North America Regional Market Trends, Size, and Future Outlook
- North America
- North America Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- North America Regional Definitions
- North America Regional Market Drivers
- High disease prevalence
- Faster drug approvals
- Supportive reimbursement infrastructure
- North America Regional Market Restraints
- Stringent approval criteria for some advanced therapies
- North America Competitive Landscape
- Europe
- Europe Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Europe Regional Definitions
- Europe Regional Market Drivers
- High disease prevalence
- Faster drug approvals
- Supportive reimbursement infrastructure
- Europe Regional Market Restraints
- Stringent approval criteria for some advanced therapies
- Europe Competitive Landscape
- Asia Pacific
- Asia Pacific Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Asia Pacific Regional Definitions
- Asia Pacific Regional Market Drivers
- High disease prevalence
- Faster drug approvals
- Supportive reimbursement infrastructure
- Asia Pacific Regional Market Restraints
- Stringent approval criteria for some advanced therapies
- Asia Pacific Competitive Landscape
- Latin America
- Latin America Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Latin America Regional Definitions
- Latin America Regional Market Drivers
- High disease prevalence
- Faster drug approvals
- Supportive reimbursement infrastructure
- Latin America Regional Market Restraints
- Stringent approval criteria for some advanced therapies
- Latin America Competitive Landscape
- Middle East and Africa
- Middle East and Africa Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Middle East and Africa Regional Definitions
- Middle East and Africa Regional Market Drivers
- High disease prevalence
- Faster drug approvals
- Supportive reimbursement infrastructure
- Middle East and Africa Regional Market Restraints
- Stringent approval criteria for some advanced therapies
- Middle East and Africa Competitive Landscape
Chapter 8. Friedreich's Ataxia Market: Competitive Landscape
- Reata Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- PTC Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Retrotope
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Neurocrine Biosciences
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Takeda
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AbbVie
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Minoryx Therapeutics S.L.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- ApoPharma
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Metro International Biotech LLC
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Design Therapeutics Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Larimar Therapeutics Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Veristat Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Chapter 8.
- Research Methodology
- Primary Research Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Appendix
- About Us
Frequently Asked Questions
The current market size is estimated at USD 1.2 billion in 2023.
Increasing research into gene and molecular therapies, Advances in genetic screening and diagnostics, Special regulatory incentives for rare disease drug development, Rising clinical trial activity, Improving healthcare infrastructure globally, Increasing patient advocacy groups and funding
The leading component segment in the Friedreich’s Ataxia Market is the gene therapy segment. Gene therapy aims to address the underlying genetic cause of Friedreich's ataxia and has curative potential.
The market is projected to grow at a CAGR of 5.8% from USD 1.2 billion in 2023 to USD 1.9 billion by 2031.
Increasing research into gene therapy and molecular treatments, Advancing genetic screening and diagnostics, Regulatory incentives for rare disease drug development, Rising pharmaceutical industry interest and clinical trial activity, Improving healthcare access globally, Patient advocacy groups and funding.